In 2006, China's pharmaceutical industry completed a total of 67.059 billion yuan in export delivery value, a year-on-year increase of 25.51%. However, the good export growth momentum is not entirely good news for Chinese pharmaceutical companies. Because exports of chemical raw materials accounted for 44.4%, a large number of low-cost exports also incurred trade friction.
The National Development and Reform Commission recently released the operational analysis of the pharmaceutical industry in 2006 and the forecast of 2007 trends. At present, China has become the world's second largest producer of pharmaceutical raw materials, and there are more than 7,000 companies engaged in the export of APIs. However, trade frictions have also increased in recent years. Qi Haisheng, secretary general of the Western Medicine Division of the China Chamber of Commerce for the Import and Export of Medicines and Health Products, said that on the one hand, some countries did not rule out the use of trade protection; on the other hand, the homogenization of Chinese APIs resulted in price failures synchronizing with exports. increase. At present, there is news that India wants to anti-dumping investigation of B12 and ceftriaxine in China.
Except for a large proportion of APIs, most of the finished drugs exported are generic drugs, which is another difficult problem facing China's pharmaceutical exports. According to Qiao Haisheng, at present, more than 97% of western medicines exported from China are generic drugs.
Correct the reason, Qiao Haisheng believes that the first R & D funds are not enough. The proportion of China's pharmaceutical companies' R&D investment to sales is basically below 5%, while the US and other large pharmaceutical companies are above 15%. Second, in our country, scientific research institutes and drug companies are out of touch, which makes it difficult for scientific research results to transform into markets. Third, China's pharmaceutical companies lack market development capabilities. One example is that the drug Artemisinin, which has intellectual property rights in China, was bought out by Novartis Switzerland.
The National Development and Reform Commission stated that during the “Eleventh Five-Year Plan†period, special export products for pharmaceutical preparations should be established to encourage the export of products with independent intellectual property rights, exact curative effects, and large international market demand, and to increase the international competitiveness of pharmaceutical products.
The National Development and Reform Commission recently released the operational analysis of the pharmaceutical industry in 2006 and the forecast of 2007 trends. At present, China has become the world's second largest producer of pharmaceutical raw materials, and there are more than 7,000 companies engaged in the export of APIs. However, trade frictions have also increased in recent years. Qi Haisheng, secretary general of the Western Medicine Division of the China Chamber of Commerce for the Import and Export of Medicines and Health Products, said that on the one hand, some countries did not rule out the use of trade protection; on the other hand, the homogenization of Chinese APIs resulted in price failures synchronizing with exports. increase. At present, there is news that India wants to anti-dumping investigation of B12 and ceftriaxine in China.
Except for a large proportion of APIs, most of the finished drugs exported are generic drugs, which is another difficult problem facing China's pharmaceutical exports. According to Qiao Haisheng, at present, more than 97% of western medicines exported from China are generic drugs.
Correct the reason, Qiao Haisheng believes that the first R & D funds are not enough. The proportion of China's pharmaceutical companies' R&D investment to sales is basically below 5%, while the US and other large pharmaceutical companies are above 15%. Second, in our country, scientific research institutes and drug companies are out of touch, which makes it difficult for scientific research results to transform into markets. Third, China's pharmaceutical companies lack market development capabilities. One example is that the drug Artemisinin, which has intellectual property rights in China, was bought out by Novartis Switzerland.
The National Development and Reform Commission stated that during the “Eleventh Five-Year Plan†period, special export products for pharmaceutical preparations should be established to encourage the export of products with independent intellectual property rights, exact curative effects, and large international market demand, and to increase the international competitiveness of pharmaceutical products.